Vitali: Cardiorrenometabolism Staging

Vitali — Cardiorrenometabolism Staging

PATIENT: —DATE: Oct 25, 2026

(1) PATIENT

Patient name

Age

yrs

Sex

Race / ethnicity

(2) VITALS

Systolic BP

mmHg

Diastolic BP

mmHg

BMI

kg/m²

Waist

Treated hypertension

On statin therapy

(3) LIPIDS

Total cholesterol

mg/dL

HDL cholesterol

mg/dL

LDL cholesterol

mg/dL

Triglycerides

mg/dL

(4) METABOLIC

HbA1c

Fasting glucose

mg/dL

Diabetes mellitus

Current smoker

(5) RENAL

Serum creatinine

mg/dL

UACR

mg/g

Estimated GFR (CKD-EPI 2021)45.0 mL/min/1.73m²

(6) CLINICAL CONTEXT

Known CVD / ASCVD

Subclinical CVD markers

(a) RISK · PREVENT 10-YR

HIGH RISK

27.7%

High risk

ASCVD 10-yr27.7%

Total CVD 10-yr40.3%

UACR-enhanced PREVENT model

<5 LOW7.5 MOD20+ HIGH

AHA CKM

Stage 2

EDMONTON

Class III

BMI 31.2 · Complicated

KDIGO

G3a A2

High risk

(b) KEY DRIVERS

Systolic BP 152 mmHg+11.0%

Type 2 diabetes Yes+9.1%

Smoking Yes+5.9%

Total cholesterol 248 mg/dL+5.9%

(c) NEXT-STEP GUIDANCE

Initiate high-intensity statin therapy; consider aspirin if bleeding risk is acceptable.

Structured CKM care: target BP <130/80 mmHg, optimize lipids, weight, and glycemic control.

Renal protection: consider ACEi/ARB and SGLT2i if appropriate; repeat eGFR and ACR.

Obesity-centered intervention: structured weight management with nutrition and activity plan.

Start a GLP-1 RA with proven cardiorenal benefit (e.g. semaglutide) alongside an SGLT2 inhibitor for combined cardiac and kidney protection.

ESTIMATION ONLY — NOT A DIAGNOSIS. VERIFY CLINICAL CONTEXT BEFORE ACTION.

(d) GLP-1 / INCRETIN THERAPY

RECOMMENDED

Start a GLP-1 RA with proven cardiorenal benefit (e.g. semaglutide) alongside an SGLT2 inhibitor for combined cardiac and kidney protection.

AGENT

GLP-1 RA with proven CV benefit (semaglutide, dulaglutide, liraglutide)

INDICATION BASIS

Type 2 diabetesHigh 10-yr ASCVD risk (27.7%)CKD (reduced eGFR and/or albuminuria)BMI 31.2 kg/m²

CAUTIONS

·Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
·Titrate slowly; monitor GI tolerance, pancreatitis symptoms, and volume status.
·Reduce sulfonylurea/insulin doses to limit hypoglycaemia risk.

DISCLOSURE

Vitali is a clinical support tool. Risk estimates and recommendations are generated from published algorithms and do not replace the physician's professional judgment or individualized clinical assessment. Always verify data and interpret results within the full clinical context before making therapeutic decisions.